European Medical Journal1d
Sotatercept Shows Long-Term Benefit in Pulmonary Arterial Hypertension Treatment
The ongoing SOTERIA study suggests that sotatercept provides a favourable long-term safety and efficacy profile for adults with pulmonary hypertension.
FDA approves new drug that may help stop a rare, fatal condition that doctors call a ‘ticking time bomb’
Then her medical team offered her a potential lifeline: a first-of-its-kind experimental drug called sotatercept that corrals ...
pharmaphorum2d
MSD leaps on FDA approval of PAH drug sotatercept
MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather than its symptoms.
TCTMD26d
Sotatercept in Contemporary PAH Treatment Algorithm
Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...
pharmaphorum7d
Merck’s cardiovascular pipeline delivers at ACC
At the American College of Cardiology (ACC) meeting this week, Merck showcased two components of its cardiovascular pipeline – sotatercept for pulmonary arterial hypertension (PAH) and oral ...
The Bakersfield Californian1mon
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...